Dermata Therapeutics, Inc. (DRMA) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of Dermata Therapeutics, Inc. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DRMA
Dermata Therapeutics, Inc.
$1.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — DRMA vs PMCB
growth of $100 · dividends reinvested · last 5yDRMA -100.0% (-84.5%/yr)PMCB -82.9% (-29.7%/yr)PMCB compounded faster over this window
Log scale — wide-divergence pair
DRMA PMCB
DRMA vs PMCB: by the numbers
- •DRMA is the larger company ($5M vs $5M market cap).
Metrics side by side
Valuation
| Metric | DRMA | PMCB |
|---|---|---|
| P/B ratio | 1.30 | 0.16 |
Profitability
| Metric | DRMA | PMCB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -239.95% | -54.15% |
| ROIC | -246.61% | -19.51% |
Growth (annualized)
| Metric | DRMA | PMCB |
|---|---|---|
| Total return CAGR (5Y) | -83.90% | -33.59% |
Frequently asked
- How have DRMA and PMCB total returns compared?
- Over the past 5 years, DRMA delivered -83.90% and PMCB delivered -33.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.